7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mitochondrial Dysfunction in the Transition from NASH to HCC

      review-article
      1 , 2 , 1 , 2 , 3 , *
      Metabolites
      MDPI
      mitochondria, metabolism, liver, NAFLD, NASH, HCC

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The liver constantly adapts to meet energy requirements of the whole body. Despite its remarkable adaptative capacity, prolonged exposure of liver cells to harmful environmental cues (such as diets rich in fat, sugar, and cholesterol) results in the development of chronic liver diseases (including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)) that can progress to hepatocellular carcinoma (HCC). The pathogenesis of these diseases is extremely complex, multifactorial, and poorly understood. Emerging evidence suggests that mitochondrial dysfunction or maladaptation contributes to detrimental effects on hepatocyte bioenergetics, reactive oxygen species (ROS) homeostasis, endoplasmic reticulum (ER) stress, inflammation, and cell death leading to NASH and HCC. The present review highlights the potential contribution of altered mitochondria function to NASH-related HCC and discusses how agents targeting this organelle could provide interesting treatment strategies for these diseases.

          Related collections

          Most cited references178

          • Record: found
          • Abstract: not found
          • Article: not found

          On the origin of cancer cells.

          O WARBURG (1956)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of mitochondria in aging.

            Over the last decade, accumulating evidence has suggested a causative link between mitochondrial dysfunction and major phenotypes associated with aging. Somatic mitochondrial DNA (mtDNA) mutations and respiratory chain dysfunction accompany normal aging, but the first direct experimental evidence that increased mtDNA mutation levels contribute to progeroid phenotypes came from the mtDNA mutator mouse. Recent evidence suggests that increases in aging-associated mtDNA mutations are not caused by damage accumulation, but rather are due to clonal expansion of mtDNA replication errors that occur during development. Here we discuss the caveats of the traditional mitochondrial free radical theory of aging and highlight other possible mechanisms, including insulin/IGF-1 signaling (IIS) and the target of rapamycin pathways, that underlie the central role of mitochondria in the aging process.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

              Nicotinamide adenine dinucleotide (NAD), the cell’s hydrogen carrier for redox enzymes, is well known for its role in redox reactions. More recently, it has emerged as a signaling molecule. By modulating NAD + sensing enzymes, it controls hundreds of key processes from energy metabolism to cell survival, rising and falling depending on food intake, exercise and the time of day. NAD + levels steadily decline with age, resulting in altered metabolism and increased disease susceptibility. Restoration of NAD + levels in old or diseased animals can promote health and extend lifespan, prompting a search for safe and efficacious NAD-boosting molecules. Such molecules hold the promise of increasing the body’s resilience, not just to one disease, but to many, thereby extending healthy human lifespan. Nicotinamide adenine nucleotide (NAD+) has emerged as a key regulator of cellular processes that control the body’s response to stress. Rajman et al. discuss NAD boosters, small molecules that raise NAD+ levels, which are now considered to be highly promising for the treatment of multiple diseases and the potential extension of human lifespan.
                Bookmark

                Author and article information

                Journal
                Metabolites
                Metabolites
                metabolites
                Metabolites
                MDPI
                2218-1989
                16 October 2019
                October 2019
                : 9
                : 10
                : 233
                Affiliations
                [1 ]Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, QC H2W 1R7, Canada; Melissa.Leveille@ 123456ircm.qc.ca
                [2 ]Faculty of Medicine, University of Montreal, Montreal, Quebec, QC H3G 2M1, Canada
                [3 ]Division of Experimental Medicine, McGill University, Montreal, Quebec, QC H4A 3J1, Canada
                Author notes
                Author information
                https://orcid.org/0000-0002-9838-1440
                Article
                metabolites-09-00233
                10.3390/metabo9100233
                6836234
                31623280
                43730720-0d3e-47cb-8c06-9a7a0192f248
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 27 August 2019
                : 11 October 2019
                Categories
                Review

                mitochondria,metabolism,liver,nafld,nash,hcc
                mitochondria, metabolism, liver, nafld, nash, hcc

                Comments

                Comment on this article